On the other hand, killing local tumor cells may reverse the immunosuppressive features of the TME, allowing for enhanced TAAs release, cross-presentation to CD8+ T cells, and recruitment of anti-tumoral effector T cells [117]. The gene discussed is CD8A; the disease is neoplasm.